PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

被引：207

作者：

King, David ^{[1
]}

Yeomanson, Daniel ^{[2
]}

Bryant, Helen E. ^{[3
]}

机构：

[1] Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England

[2] Sheffield Childrens Hosp, Dept Pediat Oncol, Sheffield S10 2TH, S Yorkshire, England

[3] Univ Sheffield, Sch Med, Dept Oncol, Acad Unit Mol Oncol, Sheffield, S Yorkshire, England

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2015年 / 37卷 / 04期

关键词：

neuroblastoma; novel; treatment; PI3K; personalized medicine; PRECLINICAL TESTING PROGRAM; REFRACTORY SOLID TUMORS; GROWTH-FACTOR RECEPTOR; IN-VIVO; PEDIATRIC-PATIENTS; PHASE-I; MAMMALIAN TARGET; DOWN-REGULATION; MYCN PROTEIN; CELL-LINES;

D O I：

10.1097/MPH.0000000000000329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neuroblastoma is the most common extracranial cancer in childhood. High-risk neuroblastoma continues to have a poor prognosis and there is an urgent need to design biologically based therapies that specifically target the pathways responsible for malignant transformation and progression. One such pathway is the PI3K/Akt/mTOR pathway. In this article we outline the evidence for aberrant activation of the PI3K/Akt/mTOR pathway in neuroblastoma and discuss the possible mechanisms which mediate it. We also discuss the development of treatments targeting this pathway in neuroblastoma and the challenges that must be overcome before such treatments can enter routine clinical practice.

引用

页码：245 / 251

页数：7

共 54 条

[1] PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis [J].

Bender, A. ;

Opel, D. ;

Naumann, I. ;

Kappler, R. ;

Friedman, L. ;

von Schweinitz, D. ;

Debatin, K-M ;

Fulda, S. .

ONCOGENE, 2011, 30 (04) :494-503

[2] The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma [J].

Berry, Teeara ;

Luther, William ;

Bhatnagar, Namrata ;

Jamin, Yann ;

Poon, Evon ;

Sanda, Takaomi ;

Pei, Desheng ;

Sharma, Bandana ;

Vetharoy, Winston R. ;

Hallsworth, Albert ;

Ahmad, Zai ;

Barker, Karen ;

Moreau, Lisa ;

Webber, Hannah ;

Wang, Wenchao ;

Liu, Qingsong ;

Perez-Atayde, Antonio ;

Rodig, Scott ;

Cheung, Nai-Kong ;

Raynaud, Florence ;

Hallberg, Bengt ;

Robinson, Simon P. ;

Gray, Nathanael S. ;

Pearson, Andrew D. J. ;

Eccles, Suzanne A. ;

Chesler, Louis ;

George, Rani E. .

CANCER CELL, 2012, 22 (01) :117-130

[3] Neuroblastoma: Biological insights into a clinical enigma [J].

Brodeur, GM .

NATURE REVIEWS CANCER, 2003, 3 (03) :203-216

[4] Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer [J].

Burger, Matthew T. ;

Pecchi, Sabina ;

Wagman, Allan ;

Ni, Zhi-Jie ;

Knapp, Mark ;

Hendrickson, Thomas ;

Atallah, Gordana ;

Pfister, Keith ;

Zhang, Yanchen ;

Bartulis, Sarah ;

Frazier, Kelly ;

Ng, Simon ;

Smith, Aaron ;

Verhagen, Joelle ;

Haznedar, Joshua ;

Huh, Kay ;

Iwanowicz, Ed ;

Xin, Xiaohua ;

Menezes, Daniel ;

Merritt, Hanne ;

Lee, Isabelle ;

Wiesmann, Marion ;

Kaufman, Susan ;

Crawford, Kenneth ;

Chin, Michael ;

Bussiere, Dirksen ;

Shoemaker, Kevin ;

Zaror, Isabel ;

Maira, Sauveur-Michel ;

Voliva, Charles F. .

ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10) :774-779

[5] Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway [J].

Burris, Howard A., III .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) :829-842

[6] Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma [J].

Chanthery, Yvan H. ;

Gustafson, W. Clay ;

Itsara, Melissa ;

Persson, Anders ;

Hackett, Christopher S. ;

Grimmer, Matt ;

Charron, Elise ;

Yakovenko, Slava ;

Kim, Grace ;

Matthay, Katherine K. ;

Weiss, William A. .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (115)

[7] Oncogenic mutations of ALK kinase in neuroblastoma [J].

Chen, Yuyan ;

Takita, Junko ;

Choi, Young Lim ;

Kato, Motohiro ;

Ohira, Miki ;

Sanada, Masashi ;

Wang, Lili ;

Soda, Manabu ;

Kikuchi, Akira ;

Igarashi, Takashi ;

Nakagawara, Akira ;

Hayashi, Yasuhide ;

Mano, Hiroyuki ;

Ogawa, Seishi .

NATURE, 2008, 455 (7215) :971-U56

[8] Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma [J].

Chesler, Louis ;

Schlieve, Chris ;

Goldenberg, David D. ;

Kenney, Anna ;

Kim, Grace ;

McMillan, Alex ;

Matthay, Katherine K. ;

Rowitch, David ;

Weiss, William A. .

CANCER RESEARCH, 2006, 66 (16) :8139-8146

[9] The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report [J].

Cohn, Susan L. ;

Pearson, Andrew D. J. ;

London, Wendy B. ;

Monclair, Tom ;

Ambros, Peter F. ;

Brodeur, Garrett M. ;

Faldum, Andreas ;

Hero, Barbara ;

Iehara, Tomoko ;

Machin, David ;

Mosseri, Veronique ;

Simon, Thorsten ;

Garaventa, Alberto ;

Castel, Victoria ;

Matthay, Katherine K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) :289-297

[10] Mutations in PIK3CA are infrequent in neuroblastoma [J].

Dam, Vincent ;

Morgan, Brian T. ;

Mazanek, Pavel ;

Hogarty, Michael D. .

BMC CANCER, 2006, 6 (1)

← 1 2 3 4 5 6 →